$TVTX
Travere Therapeutics Inc Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000143853321000053 Filed on October 29, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$57.25M	$68.22M	$50.98M
YoY Change	12.29%	33.4%	9.2%
Cost Of Revenue	$1.896M	$1.592M	$2.070M
YoY Change	-8.41%	33.89%	19.65%
Gross Profit	$55.35M	$66.63M	$48.91M
YoY Change	13.17%	33.38%	8.79%
Gross Profit Margin	96.69%	97.67%	95.93%
Selling, General & Admin	$35.85M	$36.07M	$30.08M
YoY Change	19.19%	12.88%	32.45%
% of Gross Profit	64.77%	54.13%	61.5%
Research & Development	$61.88M	$48.41M	$38.09M
YoY Change	62.45%	49.64%	5.6%
% of Gross Profit	111.78%	72.66%	77.88%
Depreciation & Amortization	$6.050M	$7.873M	$6.630M
YoY Change	-8.75%	22.25%	25.33%
% of Gross Profit	10.93%	11.82%	13.56%
Operating Expenses	$102.5M	$84.47M	$74.12M
YoY Change	38.35%	31.37%	15.99%
Operating Profit	-$47.19M	-$31.71M	-$118.6M
YoY Change	-60.19%	63.16%	320.88%
Interest Expense	-$4.833M	-$4.899M	-$380.0K
YoY Change	1171.84%	2.77%	-96.74%
% of Operating Profit
Other Income/Expense, Net	$454.0K	-$3.885M	-$3.543M
YoY Change	-112.81%	25.69%	71.99%
Pretax Income	-$51.57M	-$35.60M	-$122.1M
YoY Change	-57.76%	58.02%	303.92%
Income Tax	$4.000K	$43.00K	-$471.0K
% Of Pretax Income
Net Earnings	-$51.57M	-$35.64M	-$121.6M
YoY Change	-57.6%	58.05%	301.94%
Net Earnings / Revenue	-90.09%	-52.24%	-238.55%
Basic Earnings Per Share		-$0.59
Diluted Earnings Per Share	-$836.7K	-$0.59	-$2.371M
COMMON SHARES
Basic Shares Outstanding	61.23M shares	60.80M shares	51.05M shares
Diluted Shares Outstanding		60.80M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$427.9M	$452.8M	$356.6M
YoY Change	20.01%	13.41%	31.13%
Cash & Equivalents	$165.8M	$150.3M	$84.77M
Short-Term Investments	$262.2M	$302.5M	$271.8M
Other Short-Term Assets	$6.471M	$7.504M	$8.100M
YoY Change	-20.11%	36.44%	26.56%
Inventory	$7.313M	$6.616M	$7.608M
Prepaid Expenses
Receivables	$15.90M	$13.40M	$15.93M
Other Receivables	$247.0K	$405.0K	$17.20M
Total Short-Term Assets	$582.8M	$579.1M	$410.4M
YoY Change	42.01%	16.36%	-4.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.11M	$11.51M	$9.418M
YoY Change	17.92%	102.12%	225.77%
Goodwill	$900.0K	$936.0K	$900.0K
YoY Change	0.0%	0.0%	-3.85%
Intangibles	$148.4M		$154.1M
YoY Change	-3.69%		-1.96%
Long-Term Investments
YoY Change
Other Assets	$11.07M	$34.87M	$7.814M
YoY Change	41.66%	3.51%	-46.88%
Total Long-Term Assets	$193.8M	$196.0M	$197.0M
YoY Change	-1.64%	0.75%	12.12%
TOTAL ASSETS
Total Short-Term Assets	$582.8M	$579.1M	$410.4M
Total Long-Term Assets	$193.8M	$196.0M	$197.0M
Total Assets	$776.6M	$775.1M	$607.4M
YoY Change	27.85%	11.97%	0.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.14M	$5.830M	$12.13M
YoY Change	24.82%	-38.18%	-54.41%
Accrued Expenses	$75.18M	$63.31M	$56.79M
YoY Change	32.38%	25.81%	9.76%
Deferred Revenue	$16.27M	$16.07M	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$124.1M	$113.2M	$92.66M
YoY Change	33.92%	50.03%	-2.92%
LONG-TERM LIABILITIES
Long-Term Debt	$226.6M	$223.7M	$215.3M
YoY Change	5.24%	5.17%	5.08%
Other Long-Term Liabilities	$12.28M	$43.26M	$12.19M
YoY Change	0.7%	7.27%	-41.65%
Total Long-Term Liabilities	$12.28M	$43.26M	$12.19M
YoY Change	0.7%	7.27%	-41.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$124.1M	$113.2M	$92.66M
Total Long-Term Liabilities	$12.28M	$43.26M	$12.19M
Total Liabilities	$474.5M	$467.7M	$396.2M
YoY Change	19.76%	19.68%	3.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$766.0M	-$714.4M	-$585.9M
YoY Change	30.74%	53.88%	40.69%
Common Stock	$6.000K	$1.022B	$798.0M
YoY Change	-100.0%	33.58%	25.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$302.1M	$307.4M	$211.2M
YoY Change
Total Liabilities & Shareholders Equity	$776.6M	$775.1M	$607.4M
YoY Change	27.85%	11.97%	0.44%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	-$51.57M	-$35.64M	-$121.6M
YoY Change	-57.6%	58.05%	301.94%
Depreciation, Depletion And Amortization	$6.050M	$7.873M	$6.630M
YoY Change	-8.75%	22.25%	25.33%
Cash From Operating Activities	-$26.88M	$32.06M	-$13.87M
YoY Change	93.78%	375.71%	208.91%
INVESTING ACTIVITIES
Capital Expenditures	-$5.200M	-$5.374M	-$8.600M
YoY Change	-39.53%	-22.34%	116.08%
Acquisitions
YoY Change
Other Investing Activities	$12.57M	$37.89M	-$116.9M
YoY Change	-110.75%	-204.54%	-2202.7%
Cash From Investing Activities	$7.370M	$32.52M	-$125.5M
YoY Change	-105.87%	-175.33%	-8043.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	33.21M	2.414M	25.04M
YoY Change	32.64%	-789.71%	27722.22%
NET CHANGE
Cash From Operating Activities	-26.88M	32.06M	-13.87M
Cash From Investing Activities	7.370M	32.52M	-125.5M
Cash From Financing Activities	33.21M	2.414M	25.04M
Net Change In Cash	13.71M	67.00M	-114.3M
YoY Change	-111.99%	-282.16%	3954.61%
FREE CASH FLOW
Cash From Operating Activities	-$26.88M	$32.06M	-$13.87M
Capital Expenditures	-$5.200M	-$5.374M	-$8.600M
Free Cash Flow	-$21.68M	$37.44M	-$5.270M
YoY Change	311.33%	174.06%	933.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36257
	dei	Entity Registrant Name EntityRegistrantName	TRAVERE THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-4842691
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3611 Valley Centre Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
	dei	City Area Code CityAreaCode	888
	dei	Local Phone Number LocalPhoneNumber	969-7879
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	TVTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61226392	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150327000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84772000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	400866000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	276111000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	400857000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	276817000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13370000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15925000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	6616000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	7608000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7504000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8143000	USD
CY2021Q3	us-gaap	Income Tax Receivable IncomeTaxReceivable	405000	USD
CY2020Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	17142000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	579079000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	410407000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11513000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9418000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	34871000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33489000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	148676000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	153189000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	936000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2021Q3	us-gaap	Assets Assets	775075000	USD
CY2020Q4	us-gaap	Assets Assets	607439000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5830000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12133000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	63308000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	56793000	USD
CY2021Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10056000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6334000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16069000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2021Q3	tvtx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	17900000	USD
CY2020Q4	tvtx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	17400000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	113163000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	92660000	USD
CY2021Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	223696000	USD
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	215339000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	43262000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	40527000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	24084000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2021Q3	tvtx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	63500000	USD
CY2020Q4	tvtx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	47700000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	467705000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	396226000	USD
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61018229	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61018229	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52248431	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52248431	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1022282000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	797985000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-714393000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-585875000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-525000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-902000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	307370000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	211213000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	775075000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	607439000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	68217000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51139000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	170241000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	147338000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1592000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1189000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4888000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4054000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48407000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32349000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	148160000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	93387000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	36065000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31951000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	107808000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	100061000	USD
CY2021Q3	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	13864000	USD
CY2020Q3	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	5085000	USD
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	23960000	USD
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	7448000	USD
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	99928000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	70574000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	284816000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	204950000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-31711000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19435000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-114575000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-57612000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	654000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	553000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-223000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	788000	USD
CY2021Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	360000	USD
CY2020Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1123000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1757000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	4414000	USD
CY2021Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4899000	USD
CY2020Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4767000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-15072000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-14287000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3885000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3091000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13538000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9085000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35596000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22526000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-128113000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-66697000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	405000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18888000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-35639000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-22549000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-128518000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-47809000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.03
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60803045	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60803045	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50929575	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50929575	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59230881	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59230881	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46289103	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46289103	shares
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-35639000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-22549000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-128518000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-47809000	USD
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	216000	USD
CY2020Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-564000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	1091000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-620000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-100000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-480000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-714000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	250000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35523000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23593000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-128141000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48179000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-128518000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-47809000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20567000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17946000	USD
	tvtx	Noncash Interest Expense NoncashInterestExpense	1097000	USD
	tvtx	Noncash Interest Expense NoncashInterestExpense	1285000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1311000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-530000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8356000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7789000	USD
	tvtx	Provision Benefit For Inventory ProvisionBenefitForInventory	1372000	USD
	tvtx	Provision Benefit For Inventory ProvisionBenefitForInventory	1317000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	21524000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	16613000	USD
	tvtx	Employee Stock Purchase Plan Expense EmployeeStockPurchasePlanExpense	666000	USD
	tvtx	Employee Stock Purchase Plan Expense EmployeeStockPurchasePlanExpense	649000	USD
	tvtx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	23960000	USD
	tvtx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	7448000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5675000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-10268000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2620000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-563000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2577000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3195000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	380000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3813000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-17006000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	12220000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2045000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	20181000	USD
	tvtx	Change In Lease Assets And Liabilities Net ChangeInLeaseAssetsAndLiabilitiesNet	5823000	USD
	tvtx	Change In Lease Assets And Liabilities Net ChangeInLeaseAssetsAndLiabilitiesNet	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1908000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10213000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	40153000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-237000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	18296000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	12085000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28873000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4947000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2926000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	14004000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	13039000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	376099000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	223152000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	502141000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	143003000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-144993000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	64184000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	2065000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	6886000	USD
	tvtx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1575000	USD
	tvtx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1575000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6679000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1345000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1275000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1098000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	198470000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	102674000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-7000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	65555000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	138045000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84772000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62436000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150327000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200481000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	332303000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	318645000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6757000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5139000	USD
CY2021Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	3605000	USD
CY2020Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	914000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	48000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-100000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-479000	USD
CY2021Q3	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	216000	USD
CY2020Q3	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-566000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	228000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	261000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-35639000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-22549000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	307370000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	301413000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	211213000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	221196000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	21524000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	16613000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	6679000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	1345000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	194157000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	108692000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-714000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	250000	USD
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	1091000	USD
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-622000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1938000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1748000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-128518000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-47809000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	307370000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	301413000	USD
	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Travere Therapeutics, Inc. (“we”, “our”, “us”, “Travere” and the “Company”) refers to Travere Therapeutics, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Travere is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on identifying, developing and delivering life-changing therapies to people with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious or rare diseases and that we believe offer attractive growth characteristics. </span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ongoing novel coronavirus (COVID-19) pandemic has resulted in travel restrictions, quarantines, “stay-at-home” and “shelter-in-place” orders and extended shutdown of certain businesses around the world. While the impact of the COVID-19 pandemic did not have a material adverse effect on our financial position or results of operations for the nine months ended September 30, 2021, these governmental actions and similar actions that may be enacted in the future, and the widespread economic disruption arising from the pandemic, have the potential to materially impact our business and influence our business decisions. The extent and duration of the pandemic is unknown, and the future effects on our business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sparsentan</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> also known as RE-021, is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker (“ARB”). Sparsentan is currently being evaluated in two pivotal Phase 3 clinical studies in the following indications:</span></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#4c4c4c;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:15.42pt">Focal segmental glomerulosclerosis ("FSGS")</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is a rare kidney disease characterized by proteinuria where the glomeruli become progressively scarred. FSGS is a leading cause of end-stage renal disease.</span></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#4c4c4c;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:15.42pt">Immunoglobulin A nephropathy ("IgAN")</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is an immune-complex-mediated glomerulonephritis characterized by hematuria, proteinuria, and variable rates of progressive renal failure. IgAN is the most common primary glomerular disease.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pegtibatinase (TVT-058) is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU). Classical HCU is a rare metabolic disorder characterized by elevated levels of plasma homocysteine that can lead to vision, skeletal, circulatory and central nervous system issues. Pegtibatinase (TVT-058) is currently being tested in a Phase 1/2 double blind, randomized, placebo-controlled dose escalation study to assess its safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects in patients with classical HCU. Pegtibatinase (TVT-058) has been granted Rare Pediatric Disease and Fast Track designations by the U.S. Food and Drug Administration ("FDA"), as well as orphan drug designation in the United States and Europe. We acquired pegtibatinase (TVT-058) as part of the November 2020 acquisition of Orphan Technologies Limited.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chenodal (chenodeoxycholic acid or CDCA) is a naturally occurring bile acid that is approved for the treatment of people with radiolucent stones in the gallbladder. CTX is a rare, progressive and underdiagnosed bile acid synthesis disorder affecting many parts of the body. In January 2020, we randomized the first patients in our Phase 3 RESTORE Study to evaluate the effects of Chenodal in adult and pediatric patients with CTX, and the study enrollment remains open. The pivotal study is intended to support an NDA submission for marketing authorization of Chenodal for CTX in the United States. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is a participant in two Cooperative Research and Development Agreements ("CRADAs"), which form a multi-stakeholder approach to pool resources with leading experts, and incorporate the patient perspective early in the therapeutic identification and development process. We have partnered with the National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS") and leading patient advocacy organizations, CDG Care and Alagille Syndrome Alliance, aimed at the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome, respectively. There are no treatment options currently approved for these diseases.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Approved products:</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. </span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Cholbam® (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</span></div>•Thiola® and Thiola EC® (tiopronin tablets) are approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	376100000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	502100000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	400857000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	276817000	USD
CY2021Q3	tvtx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	302450000	USD
CY2021Q3	tvtx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	73000	USD
CY2021Q3	tvtx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	58000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	302465000	USD
CY2021Q3	tvtx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	98416000	USD
CY2021Q3	tvtx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	35000	USD
CY2021Q3	tvtx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	59000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	98392000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	400866000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	108000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	117000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	400857000	USD
CY2020Q4	tvtx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	271098000	USD
CY2020Q4	tvtx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	724000	USD
CY2020Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	22000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	271800000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	276111000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	728000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	22000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	276817000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	3600000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	197840000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	117000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	197840000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	117000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	155174000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	22000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	155174000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	22000	USD
CY2021Q3	tvtx	Number Of Operating Leases NumberOfOperatingLeases	1	lease
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	34600000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	34500000	USD
CY2020Q4	us-gaap	Incentive To Lessee IncentiveToLessee	7900000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q2	tvtx	Lessee Operating Lease Aggregate Liability LesseeOperatingLeaseAggregateLiability	49500000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1469000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6020000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6200000	USD
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23800000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6386000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6578000	USD
	tvtx	Reduction Of Operating Lease Expense ReductionOfOperatingLeaseExpense	700000	USD
CY2021Q3	tvtx	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	18535000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	45188000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8884000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	36304000	USD
CY2021Q3	tvtx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	6805000	USD
CY2021Q3	tvtx	Straight Line Lease Expense In Excess Of Cash Payments StraightLineLeaseExpenseInExcessOfCashPayments	5692000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23807000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3803000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	32501000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	36304000	USD
CY2020Q3	tvtx	Reduction Of Operating Lease Expense ReductionOfOperatingLeaseExpense	700000	USD
	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	2	business
CY2021Q3	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	280100000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	150327000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	400857000	USD
CY2021Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	551184000	USD
CY2021Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	81400000	USD
CY2021Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	81400000	USD
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	24000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	84772000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	276817000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	361589000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	65100000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	65100000	USD
CY2021Q3	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	13900000	USD
CY2020Q3	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	5100000	USD
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	7400000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	148700000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	278395000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	264676000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	129719000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	111487000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	148676000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	153189000	USD
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6344000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6023000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18432000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16482000	USD
CY2021Q3	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	280100000	USD
CY2021Q3	tvtx	Government Rebates Payable GovernmentRebatesPayable	11311000	USD
CY2020Q4	tvtx	Government Rebates Payable GovernmentRebatesPayable	10707000	USD
CY2021Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	16896000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	17912000	USD
CY2021Q3	tvtx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	8360000	USD
CY2020Q4	tvtx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	7857000	USD
CY2021Q3	tvtx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	22163000	USD
CY2020Q4	tvtx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	10166000	USD
CY2021Q3	tvtx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3117000	USD
CY2020Q4	tvtx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3944000	USD
CY2021Q3	tvtx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	1461000	USD
CY2020Q4	tvtx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	6207000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	63308000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	56793000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60803045	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60803045	shares
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-35639000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50929575	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50929575	shares
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-22549000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59230881	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59230881	shares
	us-gaap	Net Income Loss NetIncomeLoss	-128518000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.17
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46289103	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46289103	shares
	us-gaap	Net Income Loss NetIncomeLoss	-47809000	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17984802	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16911846	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18012120	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16849452	shares
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18900000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6100000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.33
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6986000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5398000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22190000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17262000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	400000	USD
CY2021Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3819000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3219000	USD
CY2021Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2797000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4389000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	6616000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	7608000	USD
CY2021Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3600000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3600000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13400000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15900000	USD
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares

Files In Submission

Name	View Source	Status
0001438533-21-000053-index-headers.html	Edgar Link	pending
0001438533-21-000053-index.html	Edgar Link	pending
0001438533-21-000053.txt	Edgar Link	pending
0001438533-21-000053-xbrl.zip	Edgar Link	pending
ex09302021101viforagreement.htm	Edgar Link	pending
ex09302021311.htm	Edgar Link	pending
ex09302021312.htm	Edgar Link	pending
ex09302021321.htm	Edgar Link	pending
ex09302021322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tvtx-20210930.htm	Edgar Link	pending
tvtx-20210930.xsd	Edgar Link	pending
tvtx-20210930_cal.xml	Edgar Link	unprocessable
tvtx-20210930_def.xml	Edgar Link	unprocessable
tvtx-20210930_g1.gif	Edgar Link	pending
tvtx-20210930_htm.xml	Edgar Link	completed
tvtx-20210930_lab.xml	Edgar Link	unprocessable
tvtx-20210930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics Inc Stock $tvtx

2021 Q4 Form 10-Q Financial Statement

#000143853321000053 Filed on October 29, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics Inc Stock $tvtx

2021 Q4 Form 10-Q Financial Statement

#000143853321000053 Filed on October 29, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics Inc Stock $tvtx